Human Organoids

Human Organoids

Global Human Organoids Market to Reach US$4.6 Billion by 2030

The global market for Human Organoids estimated at US$1.7 Billion in the year 2023, is expected to reach US$4.6 Billion by 2030, growing at a CAGR of 15.5% over the analysis period 2023-2030. Kidney Organoids, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Liver Organoids segment is estimated at 16.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$453.9 Million While China is Forecast to Grow at 20.7% CAGR

The Human Organoids market in the U.S. is estimated at US$453.9 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 20.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.7% and 13.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.4% CAGR.

Global Human Organoids Market - Key Drivers and Trends Summarized

Human organoids are three-dimensional, miniaturized, and simplified versions of human organs that are grown in vitro from stem cells. These organoids mimic the structure and function of real organs, providing a more accurate model for studying human biology and disease. They can be developed from various types of stem cells, including induced pluripotent stem cells (iPSCs) and adult stem cells, and are capable of self-organizing into organ-specific cell types. Human organoids have been created for numerous organs, including the brain, liver, kidneys, and intestines, offering a revolutionary tool for biomedical research, drug development, and personalized medicine.

The application of human organoids has significantly advanced our understanding of human development and disease mechanisms. Researchers utilize organoids to study organogenesis, model genetic disorders, and investigate the effects of various treatments in a controlled environment that closely resembles the human body. This has led to breakthroughs in identifying new drug targets and understanding the pathology of complex diseases, such as cancer, neurodegenerative disorders, and infectious diseases. Moreover, human organoids have emerged as valuable tools in regenerative medicine, where they are used to explore potential therapies for organ repair and replacement. The development of organoid technology has been accelerated by innovations in stem cell research, bioengineering, and 3D culture techniques, resulting in more sophisticated and functional models.

The growth in the human organoids market is driven by several factors. Firstly, the increasing prevalence of chronic diseases and the need for effective treatments have spurred demand for advanced research models that can accurately mimic human physiology. Secondly, advancements in stem cell technology and 3D bioprinting have facilitated the development of more complex and functional organoids. Additionally, the push for personalized medicine has boosted the adoption of organoids, as they can be derived from individual patients` cells to tailor treatments. The rising investment in biotechnology and pharmaceutical research has further propelled market growth, with substantial funding directed towards organoid research and development. Furthermore, regulatory support and collaboration between academic institutions and industry players have accelerated the commercialization of organoid-based applications. Lastly, ethical considerations favoring the use of organoids over animal models have also contributed to the market`s expansion, as they offer a more humane and potentially more accurate alternative for preclinical testing.

Select Competitors (Total 38 Featured) -

• BioIVT, LLC
• Cellaïon SA
• CN Bio Innovations Ltd
• Corning Incorporated
• CYPRIO
• InSphero AG
• KaLy-Cell
• Kirkstall Ltd.
• MIMETAS
• Organovo Holdings, Inc.
• PRIMACYT Cell Culture Technology GmbH
• Stemcell Technologies Canada, Inc.
• Thermo Fisher Scientific Inc.
• Visikol, Inc.
• WEPREDIC Group
• ZenBio, Inc;

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.